story of the week
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)
J. Clin. Oncol 2022 May 16;[EPub Ahead of Print], M Provencio, R Serna-Blasco, E Nadal, A Insa, MR García-Campelo, J Casal Rubio, M Dómine, M Majem, D Rodríguez-Abreu, A Martínez-Martí, J De Castro Carpeño, M Cobo, G López Vivanco, E Del Barco, R Bernabé Caro, N Viñolas, I Barneto Aranda, S Viteri, E Pereira, A Royuela, V Calvo, J Martín-López, F García-García, M Casarrubios, F Franco, E Sánchez-Herrero, B Massuti, A Cruz-Bermúdez, A RomeroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.